- Company
- Cephalosporin CMOs discontinue or downsize business
- by Kim, Jin-Gu May 3, 2022 06:09am
- CMO companies that have been manufacturing cephalosporin antibiotics upon consignment are either shutting down or reducing their business one after another. Given the limited number of domestic manufacturers, existing consignors are in a rush to find new consignees. Due to this, industry concerns are rising over how this breakaway among c
- Company
- GSK Consumer Healthcare Korea appoints Dongwoo Shin as CEO
- by May 3, 2022 06:09am
- GSK Consumer Healthcare Korea announced that it has appointed Dongwoo Shin (55) as the new head of its Korean subsidiary. The new General Manager has graduated from Hanyang University with a BA in Philosophy and a MA in Philosophy from the University of Rochester. After serving in various companies including Coca-Cola Korea, 20th Century
- Company
- COVID-19 vaccine SKYCovione has been applied
- by Kim, Jin-Gu May 3, 2022 06:08am
- SK Bioscience announced on the 29th that it has applied for an item permit for the COVID-19 vaccine candidate GBP510. SK Bioscience predicted that it will be able to commercialize it in the second half of the year after obtaining approval from the MFDS. The name of the vaccine applied through item approval was SKYCovione Multi Injection
- Company
- Generics for Xarelto with sales of ₩60 billion are com
- by Kim, Jin-Gu May 3, 2022 06:08am
- Competition of generic products is in full swing in the new oral anticoagulant (NOAC) market of Rivaroxaban ingredients worth 60 billion won a year. With more than 20 companies' generics pouring in in earnest since the fourth quarter of last year, Chong Kun Dang seems to be one step ahead. In the pharmaceutical industry, it is analyzed that t
- Company
- Nerlynx reattempts at reimb after failing CDDC review
- by Eo, Yun-Ho May 2, 2022 06:03am
- An adjuvant therapy drug for breast cancer, Nerlynx, that failed to receive reimbursement in its first attempt is reattempting reimbursement in Korea. According to industry sources, Bixink Therapeutics plans to apply for insurance benefits for its oral HER2 inhibitor Nerlynx (neratinib) in the second half of this year. The drug reached
- Company
- Will the flu vaccine market rebound?
- by May 2, 2022 06:03am
- As the obligation to wear outdoor masks is lifted from today, attention is being paid to whether there will be a new change in the influenza vaccine market this year. This is because the importance of flu vaccination increases as the possibility of flu infection, especially COVID-19, increases if taking off the mask. Prime Minister Kim Bu-
- Company
- Rozlytrek can be prescribed with reimb in Korea
- by Eo, Yun-Ho May 2, 2022 06:02am
- The tumor-agnostic drug Rozlytrek may now be prescribed at general hospitals in Korea. According to industry sources, Roche Korea’s NTRK(Neurotrophic tyrosine receptor kinase) targeted anticancer therapy Rozyltrek (entrectinib) has passed the drug committees of medical institutions including the Seoul National University Hospital, Sever
- Company
- Daewoong - AZ Targets Asian Market with Crezet
- by Chon, Seung-Hyun May 2, 2022 06:02am
- Daewoong Pharmaceutical, along with AstraZeneca Korea, is pushing to target the Asian market for Crezet, a hyperlipidemia treatment. Daewoong Pharmaceutical signed a cooperative contract with AstraZeneca Korea on the 27th and agreed to push for Crezet exports to Indonesia, Thailand, the Philippines, and Malaysia. Crezet is a composite of R
- Company
- The size of the DPP-4 diabetes Rx market is decreasing
- by Apr 29, 2022 05:42am
- DPP-4 inhibitor-based drugs used to treat diabetes continue to decline this year. Sales of prescriptions for major products such as Janumet, Trajenta, and Galvus fell one after another. LG Chem's Zemimet, which rose to No. 1 in the market last year, is the only top-tier item to grow, recording 23 billion won in quarterly prescriptions. Acc
- Company
- Zolgensma makes one step towards reimbursement
- by Eo, Yun-Ho Apr 29, 2022 05:42am
- Discussions on the reimbursement of ‘Zolgensma’ are finally making progress. According to industry sources, reimbursement of Novartis Korea’s Spinal Muscular Atrophy (SMA) treatment Zolgensma (onasemnogene abeparvovec-xioi) will be deliberated by the Drug Reimbursement Evaluation Committee of the National Health Insurance Service in coming
